Curelab Oncology, Inc.

Other

Università Degli Studi Di Camerino

Franco Venanzi

Michael Sherman

Alexander Shneider

Victor Shifrin

Antonio Concetti

Augusto Amici

Vladimir Gabai

Dimitrios Agas

Maria Giovanna Sabbieti

Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.

Methods and compositions relating to p62/SQSTM1 for the treatment and prevention of inflammation-associated diseases

Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.

Methods and compositions relating to P62 for the treatment and prophylaxis of cancer

Polynucleotide immunogenic agents capable of inducing an immune response towards the members of the Epidermal Growth Factor Receptors (EGFR) family are disclosed.

Polynucleotide immunogenic agents

Growing community of inventors

Camerino, Italy

Franco Venanzi